24AUG

WHO issues its first fungal blueprint

2 min read

17:07UTC

The World Health Organization published its first blueprint on fungal disease on 1 July, estimating more than 300 million people suffer serious fungal illness each year.

← Back to Guatemala's measles outbreak outgrew Mexico Jump to analysis ↓

ScienceAssessed

Key takeaway

WHO's first fungal blueprint names a 300-million-case burden that global resistance strategy had tracked only in bacteria.

The World Health Organization (WHO) published its first dedicated Blueprint on fungal disease and antifungal resistance on Wednesday 1 July, estimating that more than 300 million people suffer serious fungal disease each year ¹. The report says plainly that fungal disease is "largely absent from national health plans, global burden-of-disease estimates" and from mainstream antimicrobial resistance (AMR) strategy.

The blueprint sets four action domains and 12 national entry points, building on WHO's existing fungal priority pathogens list, which includes Candida auris, a drug-resistant yeast that spreads in hospitals and shrugs off first-line antifungals. Antimicrobial resistance is the broader field of pathogens surviving the drugs meant to kill them, and until now its surveillance counted only bacteria.

WHO's GLASS surveillance found in 2025 that one in six bacterial infections is now resistant , and the ten-year GAP-AMR plan adopted in May set targets for bacterial deaths alone . Fungi sat outside both. The blueprint is WHO's first attempt to name that omission and hand countries a governance scaffold for closing it.

Deep Analysis

In plain English

Antimicrobial resistance is when infections stop responding to the drugs normally used to treat them. Until now, global tracking of this problem has focused almost entirely on bacteria, even though fungal infections can be just as resistant and just as deadly. On 1 July, the World Health Organization published its first-ever policy document dedicated to fungal disease and antifungal resistance, estimating that more than 300 million people suffer a serious fungal infection every year. Candida auris, a drug-resistant yeast that spreads in hospitals, is one of the pathogens named in the Blueprint.

What could happen next?

Meaning
Fungal disease's inclusion in a WHO framework does not itself fund the laboratory capacity needed to track it in the countries carrying the highest burden.

Source Landscape

This story draws on neutral-leaning sources from Switzerland

Switzerland

Primary parallel: WHO's 2017 bacterial priority pathogens list named the resistance threat years before dedicated antifungal or antibacterial R&D funding followed, the same list-first, funding-later sequence this fungal Blueprint now begins.

Counter-parallel: The 2022 mpox PHEIC drew emergency funding and vaccine allocation within months of declaration, because an active outbreak with rising case counts creates faster political urgency than a standing disease-burden estimate does, a contrast suggesting this Blueprint may move at the bacterial list's slower pace rather than an outbreak's faster one.

Consensus view: The WHO Blueprint frames fungal disease as invisible by policy design, not by epidemiology, since the decade-long Global Action Plan on Antimicrobial Resistance adopted in May 2026 and the GLASS surveillance system both track bacterial resistance only, leaving an estimated 300 million annual serious fungal cases outside any global reporting mechanism.

Counter-view: Africa CDC's ARILAC laboratory-capacity programme, which found only 1.3% of assessed African laboratories conduct routine AMR testing of any kind, suggests the Blueprint's surveillance ambitions are unreachable in the same countries carrying the heaviest fungal burden until basic lab infrastructure is funded first.

Key tension: Whether naming fungal disease in a global framework accelerates funding toward the labs that need it, or simply adds an unfunded reporting requirement to systems already failing on bacterial surveillance.

Sources:WHO

Mentions:World Health Organization →WHO Blueprint on fungal disease and antifungal resistance →Candida auris →ARILAC →Africa CDC →PHEIC →

First Reported In

Update #10 · Ebola's responders are now the casualties

WHO· 14 Jul 2026

Read original →

Causes and effects

Caused by

One in six infections beats the drug

WHO GLASS's bacterial-only resistance findings left fungal disease outside AMR surveillance until this Blueprint.

Occurred 1 Jun 2026

Read story →

WHA79 adopts a 10-year AMR plan

The ten-year GAP-AMR plan adopted in May addressed bacterial resistance only, a gap the fungal Blueprint now names explicitly.

Occurred 23 May 2026

Read story →

This Event

WHO issues its first fungal blueprint

WHO's blueprint pulls fungal disease into a resistance strategy that until now tracked only bacteria.

Different Perspectives

UK Health Security Agency

UKHSA said egg consumption remains the strongest signal in its 207-case Salmonella Enteritidis investigation. The genomic cluster and 38% hospitalisation among people with available information make exposure identification a public-health priority.

GLEWS+

GLEWS+ assessed spillover risk from clade B MERS in Nile Basin camels as high if the clade establishes, while rating evidence for spread in camel populations low confidence. The joint assessment makes whole-genome sequencing the next test of the threat.

WHO Regional Office for Africa

WHO's Africa office said transmission in DR Congo is outpacing control efforts after laboratory capacity reached 19 sites and treatment capacity exceeded 1,300 beds. The assessment puts access, insecurity, community deaths and late care-seeking ahead of a simple equipment shortage.

People in Guatemala

Guatemala's population now carries the region's largest reported measles burden, with 30,371 confirmed cases and 26 deaths. The scale shifts practical attention from the Mexico-centred frame that followed the World Cup's travel consequences.

Pan American Health Organization

PAHO rated regional measles risk very high after recording 47,459 confirmed cases and 44 deaths through week 28. It names vaccination coverage, accumulated susceptibles and mass gatherings with broad international participation as general risk factors.

Chinese health authorities

China reported three human H9N2 cases to WHO between 10 and 16 July: two four-year-olds recovered, a 44-year-old man remains in intensive care, the first severity signal in a cluster that has produced 173 cases and 2 deaths globally since 2015. The subtype is distinct from the H5N1 series this topic otherwise tracks.